Description

Book Synopsis
A systematic review of the most current decision models and techniques for disease prevention and treatment Decision Analytics and Optimization in Disease Prevention and Treatmentoffers a comprehensive resource of the most current decision models and techniques for disease prevention and treatment.With contributions from leading experts in the field, this important resource presents information on the optimization of chronic disease prevention, infectious disease control and prevention, and disease treatment and treatment technology. Designed to be accessible, in each chapter the text presents one decision problem with the related methodology to showcase the vast applicability of operations research tools and techniques in advancing medical decision making. This vital resource features the most recent and effective approaches to the quickly growing field of healthcare decision analytics, which involves cost-effectiveness analysis, stochastic modeling, and computer simulation. Throug

Table of Contents

CONTRIBUTORS xiii

PREFACE xvii

PART 1 INFECTIOUS DISEASE CONTROL AND MANAGEMENT 1

1 Optimization in Infectious Disease Control and Prevention: Tuberculosis Modeling Using Microsimulation 3
Sze-chuan Suen

1.1 Tuberculosis Epidemiology and Background 4

1.1.1 TB in India 5

1.2 Microsimulations for Disease Control 6

1.3 A Microsimulation for Tuberculosis Control in India 8

1.3.1 Population Dynamics 9

1.3.2 Dynamics of TB in India 9

1.3.3 Activation 10

1.3.4 TB Treatment 11

1.3.5 Probability Conversions 13

1.3.6 Calibration and Validation 14

1.3.7 Intervention Policies and Analysis 16

1.3.8 Time Horizons and Discounting 18

1.3.9 Incremental Cost-Effectiveness Ratios and Net Monetary Benefits 19

1.3.10 Sensitivity Analysis 22

1.4 Conclusion 22

References 23

2 Saving Lives with Operations Research: Models to Improve HIV Resource Allocation 25
Sabina S. Alistar and Margaret L. Brandeau

2.1 Introduction 25

2.1.1 Background 25

2.1.2 Modeling Approaches 27

2.1.3 Chapter Overview 31

2.2 HIV Resource Allocation: Theoretical Analyses 31

2.2.1 Defining the Resource Allocation Problem 31

2.2.2 Production Functions for Prevention and Treatment Programs 35

2.2.3 Allocating Resources among Prevention and Treatment Programs 37

2.3 HIV Resource Allocation: Portfolio Analyses 39

2.3.1 Portfolio Analysis 39

2.3.2 O piate Substitution Therapy and ART in Ukraine 40

2.3.3 Pre-exposure Prophylaxis and ART 42

2.4 HIV Resource Allocation: A Tool for Decision Makers 44

2.4.1 REACH Model Overview 44

2.4.2 Example Analysis: Brazil 45

2.4.3 Example Analysis: Thailand 48

2.5 Discussion and Further Research 50

Acknowledgment 53

References 53

3 Adaptive Decision-Making During Epidemics 59
Reza Yaesoubi and Ted Cohen

3.1 Introduction 59

3.2 Problem Formulation 61

3.3 Methods 63

3.3.1 The 1918 Influenza Pandemic in San Francisco, CA 63

3.3.2 Stochastic Transmission Dynamic Models 64

3.3.3 Calibration 66

3.3.4 O ptimizing Dynamic Health Policies 69

3.4 Numerical Results 73

3.5 Conclusion 75

Acknowledgments 76

References 76

4 Assessing Register-Based Chlamydia Infection Screening Strategies: A Cost-Effectiveness Analysis on Screening Start/End Age and Frequency 81
Yu Teng, Nan Kong, and Wanzhu Tu

4.1 Introduction 81

4.2 Background Literature Review 83

4.2.1 Clinical Background on CT Infection and Control 83

4.2.2 CT Screening Programs 85

4.2.3 Computational Modeling on CT Transmission and Control 85

4.3 Mathematical Modeling 89

4.3.1 An Age-Structured Compartmental Model 89

4.3.2 Model Parameterization and Validation 93

4.4 Strategy Assessment 98

4.4.1 Base-Case Assessment 98

4.4.2 Sensitivity Analysis 100

4.5 Conclusions and Future Research 101

References 102

5 Optimal Selection of Assays for Detecting Infectious Agents in Donated Blood 109
Ebru K. Bish, Hadi El-Amine, Douglas R. Bish, Susan L. Stramer, and Anthony D. Slonim

5.1 Introduction and Challenges 109

5.1.1 Introduction 109

5.1.2 The Challenges 111

5.2 The Notation and Decision Problem 113

5.2.1 Notation 114

5.2.2 Measures of Interest 115

5.2.3 Model Formulation 117

5.2.4 Relationship of the Proposed Mathematical Models to Cost-Effectiveness Analysis 118

5.3 The Case Study of the Sub-Saharan Africa Region and the United States 119

5.3.1 Uncertainty in Prevalence Rates 122

5.4 Contributions and Future Research Directions 123

Acknowledgments 123

References 124

6 Modeling Chronic Hepatitis C During Rapid Therapeutic Advance: Cost-Effective Screening, Monitoring, and Treatment Strategies 129
Shan Liu

6.1 Introduction 129

6.2 Method 131

6.2.1 Modeling Disease Natural History and Intervention 132

6.2.2 Estimating Parameters for Disease Progression and Death 134

6.3 Four Research Areas in Designing Effective HCV Interventions 139

6.3.1 Cost-Effective Screening and Treatment Strategies 139

6.3.2 Cost-Effective Monitoring Guidelines 141

6.3.3 O ptimal Treatment Adoption Decisions 141

6.3.4 O ptimal Treatment Delivery in Integrated Healthcare Systems 145

6.4 Concluding Remarks 148

References 148

PART 2 NONCOMMUNICABLE DISEASE PREVENTION 153

7 Modeling Disease Progression and Risk-Differentiated Screening for Cervical Cancer Prevention 155
Adriana Ley-Chavez and Julia L. Higle

7.1 Introduction 155

7.2 Literature Review 157

7.3 Modeling Cervical Cancer Screening 159

7.3.1 Model Components 160

7.3.2 Parameter Selection 166

7.3.3 Implementation 169

7.4 Model-Based Analyses 171

7.4.1 Cost-Effectiveness Analysis 171

7.4.2 Sensitivity Analysis 172

7.5 Concluding Remarks 174

References 175

8 Using Finite-Horizon Markov Decision Processes for Optimizing Post-Mammography Diagnostic Decisions 183
Sait Tunc, Oguzhan Alagoz, Jagpreet Chhatwal, and Elizabeth S. Burnside

8.1 Introduction 183

8.2 Model Formulations 185

8.3 Structural Properties 188

8.4 Numerical Results 193

8.5 Summary 196

Acknowledgments 196

References 197

9 Partially Observable Markov Decision Processes for Prostate Cancer Screening, Surveillance, and Treatment: A Budgeted Sampling Approximation Method 201
Jingyu Zhang and Brian T. Denton

9.1 Introduction 201

9.2 Review of POMDP Models and Benchmark Algorithms 204

9.3 A POMDP Model for Prostate Cancer Screening, Surveillance, and Treatment 206

9.4 Budgeted Sampling Approximation 209

9.4.1 Lower and Upper Bounds 209

9.4.2 Summary of the Algorithm 211

9.5 Computational Experiments 213

9.5.1 Finite-Horizon Test Instances 213

9.5.2 Computational Experiments 214

9.6 Conclusions 217

References 219

10 Cost-Effectiveness Analysis of Breast Cancer Mammography Screening Policies Considering Uncertainty in Women’s Adherence 223
Mahboubeh Madadi and Shengfan Zhang

10.1 Introduction 223

10.2 Model Formulation 225

10.3 Numerical Studies 231

10.4 Results 233

10.4.1 Perfect Adherence Case 233

10.4.2 General Population Adherence Case 234

10.5 Summary 236

References 237

11 An Agent-Based Model for Ideal Cardiovascular Health 241
Yan Li, Nan Kong, Mark A. Lawley, and José A. Pagán

11.1 Introduction 241

11.2 Methodology 243

11.2.1 Agent-Based Modeling 243

11.2.2 Model Structure 244

11.2.3 Parameter Estimation 246

11.2.4 User Interface 248

11.2.5 Model Validation 249

11.3 Results 250

11.3.1 Simulating American Adults 250

11.4 Simulating the Medicare-Age Population and the Disease-Specific Subpopulations 252

11.5 Future Research 254

11.6 Summary 255

References 255

PART 3 TREATMENT TECHNOLOGY AND SYSTEM 259

12 Biological Planning Optimization for High-Dose-Rate Brachytherapy and its Application to Cervical Cancer Treatment 261
Eva K. Lee, Fan Yuan, Alistair Templeton, Rui Yao, Krystyna Kiel, and James C.H. Chu

12.1 Introduction 261

12.2 Challenges and Objectives 263

12.3 Materials and Methods 265

12.3.1 High-Dose-Rate Brachytherapy 265

12.3.2 PET Image 266

12.3.3 Novel OR-Based Treatment-Planning Model 266

12.3.4 Computational Challenges and Solution Strategies 271

12.4 Validation and Results 273

12.5 Findings, Implementation, and Challenges 276

12.6 Impact and Significance 279

12.6.1 Quality of Care and Quality of Life for Patients 279

12.6.2 Advancing the Cancer Treatment Frontier 279

12.6.3 Advances in Operations Research Methodologies 280

Acknowledgment 281

References 281

13 Fluence Map Optimization in Intensity-Modulated Radiation Therapy Treatment Planning 285
Dionne M. Aleman

13.1 Introduction 285

13.2 Treatment Plan Evaluation 288

13.2.1 Physical Dose Measures 289

13.2.2 Biological Dose Measures 291

13.3 FMO Optimization Models 292

13.3.1 O bjective Functions 293

13.3.2 Constraints 295

13.3.3 Robust Formulation 297

13.4 O ptimization Approaches 299

13.5 Conclusions 300

References 301

14 Sliding Window IMRT and VMAT Optimization 307
David Craft and Tarek Halabi

14.1 Introduction 307

14.2 Two-Step IMRT Planning 309

14.3 O ne-Step IMRT Planning 310

14.3.1 O ne-Step Sliding Window Optimization 310

14.4 Volumetric Modulated ARC Therapy 313

14.5 Future Work for Radiotherapy Optimization 315

14.5.1 Custom Solver for Radiotherapy 315

14.5.2 Incorporating Additional Hardware Considerations into Sliding Window VMAT Planning 315

14.5.3 Trade-Off between Delivery Time and Plan Quality 316

14.5.4 What Do We Optimize? 316

14.6 Concluding Thoughts 317

References 318

15 Modeling the Cardiovascular Disease Prevention–Treatment Trade-Off 323
George Miller

15.1 Introduction 323

15.2 Methods 325

15.2.1 Model Overview 325

15.2.2 Model Structure 327

15.2.3 Model Inputs 331

15.3 Results 334

15.3.1 Base Case 334

15.3.2 Interaction between Prevention and Treatment Spending 335

15.3.3 Impact of Discount Rate on Cost-Effectiveness 336

15.3.4 O ptimal Spending Mix 337

15.3.5 Impact of Prevention Lag on Optimal Mix 338

15.3.6 Impact of Discount Rate on Optimal Mix 340

15.3.7 Impact of Time Horizon on Optimal Mix 340

15.3.8 Impacts of Research 341

15.4 Discussion 344

Acknowledgment 346

References 346

16 Treatment Optimization for Patients with Type 2 Diabetes 349
Jennifer Mason Lobo

16.1 Introduction 349

16.2 Literature Review 350

16.3 Model Formulation 353

16.3.1 Decision Epochs 354

16.3.2 States 354

16.3.3 Actions 355

16.3.4 Probabilities 355

16.3.5 Rewards 356

16.3.6 Value Function 356

16.4 Numerical Results 357

16.4.1 Model Inputs 357

16.4.2 Optimal Treatment Policies to Reduce Polypharmacy 358

16.5 Conclusions 362

References 363

17 Machine Learning for Early Detection and Treatment Outcome Prediction 367
Eva K. Lee

17.1 Introduction 367

17.2 Background 369

17.3 Machine Learning with Discrete Support Vector Machine Predictive Models 372

17.3.1 Modeling of Reserved-Judgment Region for General Groups 373

17.3.2 Discriminant Analysis via Mixed-Integer Programming 374

17.3.3 Model Variations 376

17.3.4 Theoretical Properties and Computational Strategies 379

17.4 Applying Damip to Real-World Applications 380

17.4.1 Validation of Model and Computational Effort 381

17.4.2 Applications to Biological and Medical Problems 381

17.4.3 Applying DAMIP to UCI Repository of Machine Learning Databases 389

17.5 Summary and Conclusion 393

Acknowledgment 394

References 394

INDEX 401

Decision Analytics and Optimization in Disease

    Product form

    £89.96

    Includes FREE delivery

    RRP £99.95 – you save £9.99 (9%)

    Order before 4pm today for delivery by Sat 8 Aug 2026.

    A Hardback by Nan Kong, Shengfan Zhang

    3 in stock

      Trusted by thousands of customers. See 2,385+ Customer Reviews

      View other formats and editions of Decision Analytics and Optimization in Disease by Nan Kong

      Publisher: John Wiley & Sons Inc
      Publication Date: Publication Date: 24/04/2018
      ISBN13: 9781118960127, 978-1118960127
      ISBN10: 1118960122

      Description

      Book Synopsis
      A systematic review of the most current decision models and techniques for disease prevention and treatment Decision Analytics and Optimization in Disease Prevention and Treatmentoffers a comprehensive resource of the most current decision models and techniques for disease prevention and treatment.With contributions from leading experts in the field, this important resource presents information on the optimization of chronic disease prevention, infectious disease control and prevention, and disease treatment and treatment technology. Designed to be accessible, in each chapter the text presents one decision problem with the related methodology to showcase the vast applicability of operations research tools and techniques in advancing medical decision making. This vital resource features the most recent and effective approaches to the quickly growing field of healthcare decision analytics, which involves cost-effectiveness analysis, stochastic modeling, and computer simulation. Throug

      Table of Contents

      CONTRIBUTORS xiii

      PREFACE xvii

      PART 1 INFECTIOUS DISEASE CONTROL AND MANAGEMENT 1

      1 Optimization in Infectious Disease Control and Prevention: Tuberculosis Modeling Using Microsimulation 3
      Sze-chuan Suen

      1.1 Tuberculosis Epidemiology and Background 4

      1.1.1 TB in India 5

      1.2 Microsimulations for Disease Control 6

      1.3 A Microsimulation for Tuberculosis Control in India 8

      1.3.1 Population Dynamics 9

      1.3.2 Dynamics of TB in India 9

      1.3.3 Activation 10

      1.3.4 TB Treatment 11

      1.3.5 Probability Conversions 13

      1.3.6 Calibration and Validation 14

      1.3.7 Intervention Policies and Analysis 16

      1.3.8 Time Horizons and Discounting 18

      1.3.9 Incremental Cost-Effectiveness Ratios and Net Monetary Benefits 19

      1.3.10 Sensitivity Analysis 22

      1.4 Conclusion 22

      References 23

      2 Saving Lives with Operations Research: Models to Improve HIV Resource Allocation 25
      Sabina S. Alistar and Margaret L. Brandeau

      2.1 Introduction 25

      2.1.1 Background 25

      2.1.2 Modeling Approaches 27

      2.1.3 Chapter Overview 31

      2.2 HIV Resource Allocation: Theoretical Analyses 31

      2.2.1 Defining the Resource Allocation Problem 31

      2.2.2 Production Functions for Prevention and Treatment Programs 35

      2.2.3 Allocating Resources among Prevention and Treatment Programs 37

      2.3 HIV Resource Allocation: Portfolio Analyses 39

      2.3.1 Portfolio Analysis 39

      2.3.2 O piate Substitution Therapy and ART in Ukraine 40

      2.3.3 Pre-exposure Prophylaxis and ART 42

      2.4 HIV Resource Allocation: A Tool for Decision Makers 44

      2.4.1 REACH Model Overview 44

      2.4.2 Example Analysis: Brazil 45

      2.4.3 Example Analysis: Thailand 48

      2.5 Discussion and Further Research 50

      Acknowledgment 53

      References 53

      3 Adaptive Decision-Making During Epidemics 59
      Reza Yaesoubi and Ted Cohen

      3.1 Introduction 59

      3.2 Problem Formulation 61

      3.3 Methods 63

      3.3.1 The 1918 Influenza Pandemic in San Francisco, CA 63

      3.3.2 Stochastic Transmission Dynamic Models 64

      3.3.3 Calibration 66

      3.3.4 O ptimizing Dynamic Health Policies 69

      3.4 Numerical Results 73

      3.5 Conclusion 75

      Acknowledgments 76

      References 76

      4 Assessing Register-Based Chlamydia Infection Screening Strategies: A Cost-Effectiveness Analysis on Screening Start/End Age and Frequency 81
      Yu Teng, Nan Kong, and Wanzhu Tu

      4.1 Introduction 81

      4.2 Background Literature Review 83

      4.2.1 Clinical Background on CT Infection and Control 83

      4.2.2 CT Screening Programs 85

      4.2.3 Computational Modeling on CT Transmission and Control 85

      4.3 Mathematical Modeling 89

      4.3.1 An Age-Structured Compartmental Model 89

      4.3.2 Model Parameterization and Validation 93

      4.4 Strategy Assessment 98

      4.4.1 Base-Case Assessment 98

      4.4.2 Sensitivity Analysis 100

      4.5 Conclusions and Future Research 101

      References 102

      5 Optimal Selection of Assays for Detecting Infectious Agents in Donated Blood 109
      Ebru K. Bish, Hadi El-Amine, Douglas R. Bish, Susan L. Stramer, and Anthony D. Slonim

      5.1 Introduction and Challenges 109

      5.1.1 Introduction 109

      5.1.2 The Challenges 111

      5.2 The Notation and Decision Problem 113

      5.2.1 Notation 114

      5.2.2 Measures of Interest 115

      5.2.3 Model Formulation 117

      5.2.4 Relationship of the Proposed Mathematical Models to Cost-Effectiveness Analysis 118

      5.3 The Case Study of the Sub-Saharan Africa Region and the United States 119

      5.3.1 Uncertainty in Prevalence Rates 122

      5.4 Contributions and Future Research Directions 123

      Acknowledgments 123

      References 124

      6 Modeling Chronic Hepatitis C During Rapid Therapeutic Advance: Cost-Effective Screening, Monitoring, and Treatment Strategies 129
      Shan Liu

      6.1 Introduction 129

      6.2 Method 131

      6.2.1 Modeling Disease Natural History and Intervention 132

      6.2.2 Estimating Parameters for Disease Progression and Death 134

      6.3 Four Research Areas in Designing Effective HCV Interventions 139

      6.3.1 Cost-Effective Screening and Treatment Strategies 139

      6.3.2 Cost-Effective Monitoring Guidelines 141

      6.3.3 O ptimal Treatment Adoption Decisions 141

      6.3.4 O ptimal Treatment Delivery in Integrated Healthcare Systems 145

      6.4 Concluding Remarks 148

      References 148

      PART 2 NONCOMMUNICABLE DISEASE PREVENTION 153

      7 Modeling Disease Progression and Risk-Differentiated Screening for Cervical Cancer Prevention 155
      Adriana Ley-Chavez and Julia L. Higle

      7.1 Introduction 155

      7.2 Literature Review 157

      7.3 Modeling Cervical Cancer Screening 159

      7.3.1 Model Components 160

      7.3.2 Parameter Selection 166

      7.3.3 Implementation 169

      7.4 Model-Based Analyses 171

      7.4.1 Cost-Effectiveness Analysis 171

      7.4.2 Sensitivity Analysis 172

      7.5 Concluding Remarks 174

      References 175

      8 Using Finite-Horizon Markov Decision Processes for Optimizing Post-Mammography Diagnostic Decisions 183
      Sait Tunc, Oguzhan Alagoz, Jagpreet Chhatwal, and Elizabeth S. Burnside

      8.1 Introduction 183

      8.2 Model Formulations 185

      8.3 Structural Properties 188

      8.4 Numerical Results 193

      8.5 Summary 196

      Acknowledgments 196

      References 197

      9 Partially Observable Markov Decision Processes for Prostate Cancer Screening, Surveillance, and Treatment: A Budgeted Sampling Approximation Method 201
      Jingyu Zhang and Brian T. Denton

      9.1 Introduction 201

      9.2 Review of POMDP Models and Benchmark Algorithms 204

      9.3 A POMDP Model for Prostate Cancer Screening, Surveillance, and Treatment 206

      9.4 Budgeted Sampling Approximation 209

      9.4.1 Lower and Upper Bounds 209

      9.4.2 Summary of the Algorithm 211

      9.5 Computational Experiments 213

      9.5.1 Finite-Horizon Test Instances 213

      9.5.2 Computational Experiments 214

      9.6 Conclusions 217

      References 219

      10 Cost-Effectiveness Analysis of Breast Cancer Mammography Screening Policies Considering Uncertainty in Women’s Adherence 223
      Mahboubeh Madadi and Shengfan Zhang

      10.1 Introduction 223

      10.2 Model Formulation 225

      10.3 Numerical Studies 231

      10.4 Results 233

      10.4.1 Perfect Adherence Case 233

      10.4.2 General Population Adherence Case 234

      10.5 Summary 236

      References 237

      11 An Agent-Based Model for Ideal Cardiovascular Health 241
      Yan Li, Nan Kong, Mark A. Lawley, and José A. Pagán

      11.1 Introduction 241

      11.2 Methodology 243

      11.2.1 Agent-Based Modeling 243

      11.2.2 Model Structure 244

      11.2.3 Parameter Estimation 246

      11.2.4 User Interface 248

      11.2.5 Model Validation 249

      11.3 Results 250

      11.3.1 Simulating American Adults 250

      11.4 Simulating the Medicare-Age Population and the Disease-Specific Subpopulations 252

      11.5 Future Research 254

      11.6 Summary 255

      References 255

      PART 3 TREATMENT TECHNOLOGY AND SYSTEM 259

      12 Biological Planning Optimization for High-Dose-Rate Brachytherapy and its Application to Cervical Cancer Treatment 261
      Eva K. Lee, Fan Yuan, Alistair Templeton, Rui Yao, Krystyna Kiel, and James C.H. Chu

      12.1 Introduction 261

      12.2 Challenges and Objectives 263

      12.3 Materials and Methods 265

      12.3.1 High-Dose-Rate Brachytherapy 265

      12.3.2 PET Image 266

      12.3.3 Novel OR-Based Treatment-Planning Model 266

      12.3.4 Computational Challenges and Solution Strategies 271

      12.4 Validation and Results 273

      12.5 Findings, Implementation, and Challenges 276

      12.6 Impact and Significance 279

      12.6.1 Quality of Care and Quality of Life for Patients 279

      12.6.2 Advancing the Cancer Treatment Frontier 279

      12.6.3 Advances in Operations Research Methodologies 280

      Acknowledgment 281

      References 281

      13 Fluence Map Optimization in Intensity-Modulated Radiation Therapy Treatment Planning 285
      Dionne M. Aleman

      13.1 Introduction 285

      13.2 Treatment Plan Evaluation 288

      13.2.1 Physical Dose Measures 289

      13.2.2 Biological Dose Measures 291

      13.3 FMO Optimization Models 292

      13.3.1 O bjective Functions 293

      13.3.2 Constraints 295

      13.3.3 Robust Formulation 297

      13.4 O ptimization Approaches 299

      13.5 Conclusions 300

      References 301

      14 Sliding Window IMRT and VMAT Optimization 307
      David Craft and Tarek Halabi

      14.1 Introduction 307

      14.2 Two-Step IMRT Planning 309

      14.3 O ne-Step IMRT Planning 310

      14.3.1 O ne-Step Sliding Window Optimization 310

      14.4 Volumetric Modulated ARC Therapy 313

      14.5 Future Work for Radiotherapy Optimization 315

      14.5.1 Custom Solver for Radiotherapy 315

      14.5.2 Incorporating Additional Hardware Considerations into Sliding Window VMAT Planning 315

      14.5.3 Trade-Off between Delivery Time and Plan Quality 316

      14.5.4 What Do We Optimize? 316

      14.6 Concluding Thoughts 317

      References 318

      15 Modeling the Cardiovascular Disease Prevention–Treatment Trade-Off 323
      George Miller

      15.1 Introduction 323

      15.2 Methods 325

      15.2.1 Model Overview 325

      15.2.2 Model Structure 327

      15.2.3 Model Inputs 331

      15.3 Results 334

      15.3.1 Base Case 334

      15.3.2 Interaction between Prevention and Treatment Spending 335

      15.3.3 Impact of Discount Rate on Cost-Effectiveness 336

      15.3.4 O ptimal Spending Mix 337

      15.3.5 Impact of Prevention Lag on Optimal Mix 338

      15.3.6 Impact of Discount Rate on Optimal Mix 340

      15.3.7 Impact of Time Horizon on Optimal Mix 340

      15.3.8 Impacts of Research 341

      15.4 Discussion 344

      Acknowledgment 346

      References 346

      16 Treatment Optimization for Patients with Type 2 Diabetes 349
      Jennifer Mason Lobo

      16.1 Introduction 349

      16.2 Literature Review 350

      16.3 Model Formulation 353

      16.3.1 Decision Epochs 354

      16.3.2 States 354

      16.3.3 Actions 355

      16.3.4 Probabilities 355

      16.3.5 Rewards 356

      16.3.6 Value Function 356

      16.4 Numerical Results 357

      16.4.1 Model Inputs 357

      16.4.2 Optimal Treatment Policies to Reduce Polypharmacy 358

      16.5 Conclusions 362

      References 363

      17 Machine Learning for Early Detection and Treatment Outcome Prediction 367
      Eva K. Lee

      17.1 Introduction 367

      17.2 Background 369

      17.3 Machine Learning with Discrete Support Vector Machine Predictive Models 372

      17.3.1 Modeling of Reserved-Judgment Region for General Groups 373

      17.3.2 Discriminant Analysis via Mixed-Integer Programming 374

      17.3.3 Model Variations 376

      17.3.4 Theoretical Properties and Computational Strategies 379

      17.4 Applying Damip to Real-World Applications 380

      17.4.1 Validation of Model and Computational Effort 381

      17.4.2 Applications to Biological and Medical Problems 381

      17.4.3 Applying DAMIP to UCI Repository of Machine Learning Databases 389

      17.5 Summary and Conclusion 393

      Acknowledgment 394

      References 394

      INDEX 401

      Recently viewed products

      © 2026 Book Curl

        • American Express
        • Apple Pay
        • Diners Club
        • Discover
        • Google Pay
        • Maestro
        • Mastercard
        • PayPal
        • Shop Pay
        • Union Pay
        • Visa

        Login

        Forgot your password?

        Don't have an account yet?
        Create account